IL145876A0 - Methods and kits for improving vascular health - Google Patents
Methods and kits for improving vascular healthInfo
- Publication number
- IL145876A0 IL145876A0 IL14587601A IL14587601A IL145876A0 IL 145876 A0 IL145876 A0 IL 145876A0 IL 14587601 A IL14587601 A IL 14587601A IL 14587601 A IL14587601 A IL 14587601A IL 145876 A0 IL145876 A0 IL 145876A0
- Authority
- IL
- Israel
- Prior art keywords
- kits
- improving
- methods
- vascular health
- improving vascular
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24153200P | 2000-10-17 | 2000-10-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL145876A0 true IL145876A0 (en) | 2002-07-25 |
Family
ID=22911075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14587601A IL145876A0 (en) | 2000-10-17 | 2001-10-11 | Methods and kits for improving vascular health |
Country Status (18)
Country | Link |
---|---|
US (1) | US6620806B2 (xx) |
EP (1) | EP1199071B1 (xx) |
JP (1) | JP2002145773A (xx) |
KR (1) | KR20020030725A (xx) |
AT (1) | ATE326962T1 (xx) |
AU (1) | AU778095B2 (xx) |
CA (1) | CA2358840C (xx) |
CY (1) | CY1105066T1 (xx) |
DE (1) | DE60119868T2 (xx) |
DK (1) | DK1199071T3 (xx) |
ES (1) | ES2263562T3 (xx) |
HU (1) | HUP0104338A3 (xx) |
IL (1) | IL145876A0 (xx) |
MY (1) | MY121479A (xx) |
NZ (1) | NZ514847A (xx) |
PT (1) | PT1199071E (xx) |
TW (1) | TWI303990B (xx) |
ZA (1) | ZA200108444B (xx) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7670612B2 (en) | 2002-04-10 | 2010-03-02 | Innercap Technologies, Inc. | Multi-phase, multi-compartment capsular delivery apparatus and methods for using same |
US7572780B2 (en) * | 2003-01-21 | 2009-08-11 | Dimera, Incorporated | Method and kit for reducing the symptoms of peripheral vascular disease |
MY151322A (en) * | 2004-04-30 | 2014-05-15 | Bayer Ip Gmbh | Management of breakthrough bleeding in extended hormonal contraceptive regimens |
US20060106647A1 (en) * | 2004-11-18 | 2006-05-18 | Brummel Anthony C | Method and apparatus for determining pharmacy order parameters based on patient context data |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6204284B1 (en) | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US5407955A (en) * | 1994-02-18 | 1995-04-18 | Eli Lilly And Company | Methods for lowering serum cholesterol and inhibiting smooth muscle cell proliferation, restenosis, endometriosis, and uterine fibroid disease |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
US5552412A (en) | 1995-01-09 | 1996-09-03 | Pfizer Inc | 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis |
US5726168A (en) | 1995-10-12 | 1998-03-10 | Eli Lilly And Company | Lipophilic benzothiophenes |
UA51676C2 (uk) | 1995-11-02 | 2002-12-16 | Пфайзер Інк. | (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
TW442286B (en) | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
IL120265A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
US5747509A (en) | 1996-06-03 | 1998-05-05 | Schering Aktiengesellschaft | Method for lowering plasma levels of lipoprotein(a) |
AR008155A1 (es) | 1996-09-06 | 1999-12-09 | Smithkline Beecham Corp | Uso de un compuesto de formula i para preparar un medicamento util para tratar y prevenir la enfermedad cardiovascular post menopausica en mujeres. |
US6034102A (en) | 1996-11-15 | 2000-03-07 | Pfizer Inc | Atherosclerosis treatment |
US6069175A (en) * | 1996-11-15 | 2000-05-30 | Pfizer Inc. | Estrogen agonist/antagonists treatment of atherosclerosis |
US6114395A (en) * | 1996-11-15 | 2000-09-05 | Pfizer Inc. | Method of treating atherosclerosis |
ZA987554B (en) | 1997-08-21 | 2000-02-21 | American Home Prod | Methods for the solid phase synthesis of substituted indole compounds. |
US5990129A (en) | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
US5968918A (en) | 1997-10-17 | 1999-10-19 | Kanda; Iwao | Method for the prevention of coronary artery spasm |
DE19812204A1 (de) | 1998-03-19 | 1999-11-04 | Plantamed Arzneimittel Gmbh | Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung |
US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
CO5271696A1 (es) * | 2000-01-12 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para reducir la morbilidad y el riesgo de mortalidad |
-
2001
- 2001-10-11 TW TW090125130A patent/TWI303990B/zh not_active IP Right Cessation
- 2001-10-11 IL IL14587601A patent/IL145876A0/xx unknown
- 2001-10-12 AU AU79392/01A patent/AU778095B2/en not_active Ceased
- 2001-10-15 CA CA002358840A patent/CA2358840C/en not_active Expired - Fee Related
- 2001-10-15 ZA ZA200108444A patent/ZA200108444B/xx unknown
- 2001-10-15 MY MYPI20014790A patent/MY121479A/en unknown
- 2001-10-15 US US09/977,458 patent/US6620806B2/en not_active Expired - Fee Related
- 2001-10-16 HU HU0104338A patent/HUP0104338A3/hu unknown
- 2001-10-16 JP JP2001317833A patent/JP2002145773A/ja active Pending
- 2001-10-16 ES ES01308806T patent/ES2263562T3/es not_active Expired - Lifetime
- 2001-10-16 NZ NZ514847A patent/NZ514847A/xx unknown
- 2001-10-16 DE DE60119868T patent/DE60119868T2/de not_active Expired - Fee Related
- 2001-10-16 PT PT01308806T patent/PT1199071E/pt unknown
- 2001-10-16 AT AT01308806T patent/ATE326962T1/de not_active IP Right Cessation
- 2001-10-16 DK DK01308806T patent/DK1199071T3/da active
- 2001-10-16 EP EP01308806A patent/EP1199071B1/en not_active Expired - Lifetime
- 2001-10-17 KR KR1020010063882A patent/KR20020030725A/ko not_active Application Discontinuation
-
2006
- 2006-07-03 CY CY20061100904T patent/CY1105066T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP1199071A2 (en) | 2002-04-24 |
DE60119868D1 (de) | 2006-06-29 |
ZA200108444B (en) | 2003-04-15 |
EP1199071A3 (en) | 2003-10-29 |
AU7939201A (en) | 2002-04-18 |
HU0104338D0 (en) | 2001-12-28 |
MY121479A (en) | 2006-01-28 |
US20020156090A1 (en) | 2002-10-24 |
ES2263562T3 (es) | 2006-12-16 |
KR20020030725A (ko) | 2002-04-25 |
HUP0104338A3 (en) | 2004-06-28 |
HUP0104338A2 (hu) | 2002-07-29 |
DE60119868T2 (de) | 2006-11-30 |
TWI303990B (en) | 2008-12-11 |
DK1199071T3 (da) | 2006-08-21 |
ATE326962T1 (de) | 2006-06-15 |
US6620806B2 (en) | 2003-09-16 |
PT1199071E (pt) | 2006-09-29 |
EP1199071B1 (en) | 2006-05-24 |
CA2358840C (en) | 2007-02-13 |
AU778095B2 (en) | 2004-11-18 |
CY1105066T1 (el) | 2010-03-03 |
CA2358840A1 (en) | 2002-04-17 |
JP2002145773A (ja) | 2002-05-22 |
NZ514847A (en) | 2003-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03006728A (es) | Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares. | |
MXPA02012410A (es) | Metodo para tratar enfermedades cardiovasculares usando rapamicina. | |
CA2434682A1 (en) | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | |
MXPA03006729A (es) | Utilizacion de compuestos de azetidinona sustituida para el tratamiento de la sitosterolemia. | |
HK1069767A1 (en) | Methods for inhibiting ocular processes | |
WO2000002576A3 (en) | Egf-genistein for prevention of restenosis | |
SE9901462D0 (sv) | Novel compound | |
TW200500361A (en) | Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions | |
ES2216630T3 (es) | Metodos de tratar la hipertension dependiente de la sal. | |
WO2004058185A3 (en) | Antiangiogenesis by inhibiting protein kinase ck2 activity | |
DK1075277T4 (da) | Fremgangsmåder til detektion og inhibering af angiogenese | |
ZA200108130B (en) | Treatment of pulmonary hypertension. | |
ZA200108444B (en) | Methods and kits for improving vascular health. | |
EP0978284A4 (en) | ENDOTHELIN ANTAGONIST | |
WO2006102611A3 (en) | Therapeutic agents for the treatment of leukemia | |
AU2002358665A1 (en) | Process for determining the odor-inhibiting properties of textile auxiliaries | |
WO2004080271A3 (en) | Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof | |
ZA997446B (en) | Lowering blood levels of lipoprotein(a). | |
CA2534489A1 (en) | Inhibitors of cathepsin s | |
DE69941292D1 (de) | Schlange, pseudonaja textilis textilis | |
GB0026236D0 (en) | Fixation instrument for arterial graft | |
EP1709974A3 (en) | Method of treating cardiovascular disease using rapamycin | |
GT199900039A (es) | Combinaciones de estatina-inhibidor de mmp. | |
BR0012072A (pt) | Processo para o tratamento ou prevenção de vasoespasmo de enxerto coronário | |
WO2002038035A3 (en) | Methods for inhibiting pain |